Clinical Trials
83 trialsOUTREACH
Mina Alpha Limited
HCC
Sinocelltech Ltd.
Viale-a
The Second Affiliated Hospital of Kunming Medical University
HAIC Plus Toripalimab vs. HAIC Plus Sorafenib for HCC With PVTT: a Non-comparative, Prospective, Randomized Trial
Sun Yat-sen University
SCCLG-M5
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Microvascular Invasion for Guiding Treatment of Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma
Sun Yat-sen University
SBRT+TACE+Sorafenib Vs Sorafenib in the Treatment of uHCC With PVTT
First Affiliated Hospital of Zhejiang University
TACE+Tilelizumab+Sorafenib in the Treatment of BCLC Stage C HCC
First Affiliated Hospital of Zhejiang University
The Gut Microbiome and Sorafenib Maintenance Therapy in FLT3-ITD Positive AML After Allo-HSCT
Nanfang Hospital, Southern Medical University
The Gut Microbiome in FLT3-ITD+ AML Undergoing Allo-HSCT With Or Without Sorafenib Maintenance After Allo-HSCT
Nanfang Hospital, Southern Medical University
Assessment of the Efficacy of Lenvatinib Versus Sorafenib in the Management of Advanced Hepatocellular Carcinoma
Sir Salimullah Medical College Mitford Hospital
TACE-SBRT
Tata Memorial Hospital
Effect and Safety of Recombinant Human Adenovirus Type 5 in Advanced HCC With Stable Disease After Sorafenib Treatment
First Affiliated Hospital Xi'an Jiaotong University
Individualized Induction Therapy for Non-elderly Acute Myeloid Leukemia Patients With Adverse Risk Features
The First Affiliated Hospital of Soochow University
Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone
Thomas Jefferson University
Evaluate the Efficacy of Sorafenib in Renal Cell Carcinoma Patients After a Radical Resection of the Metastases
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Lenvatinib Plus TACE Versus Sorafenib Plus TACE for HCC With PVTT
Beijing Ditan Hospital
Toripalimab
Shanghai Zhongshan Hospital
A Randomized Phase II Trial of Surgery Plus Sorafenib vs. Sorafenib Alone for Hepatocellular Cancer (HCC) With Portal Vein Invasion
White Plains Hospital
DEB-TACE Plus Lenvatinib or Sorafenib or PD-1 Inhibitor for Unresectable Hepatocellular Carcinoma
Guangxi Medical University
A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma.
Innovent Biologics (Suzhou) Co. Ltd.
DKN-01 Inhibition in Advanced Liver Cancer
Johannes Gutenberg University Mainz
SOURCE
Sun Yat-sen University
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy
Samsung Medical Center
Clinical Trial for GALNT14 Genotype - Guided, Sorafenib in Combination With TACE in Hepatocellular Carcinoma
Chang Gung Memorial Hospital
A-TACE/S-HCC
Guangxi Medical University
Combined Immunotherapy and Targeted Therapy for Advanced Liver Cancer
Guangxi Medical University
Combined Immunotherapy and Targeted Therapy for Hepatocellular Carcinoma
Guangxi Medical University
STUHCCPVTT
Sichuan University
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma
King Saud University
TACE With or Without Sorafenib in Intermediate Stage Hepatocellular Carcinoma
Air Force Military Medical University, China
Phase 2b Study of Taxol Plus Sorafenib or Placebo in Patients With Advanced Breast Cancer
Northwestern University
Phase 2 Study of Sorafenib Plus HAIC of FOLFOX vs. Sorafenib Plus HAIC of OXA for Advanced HCC
Sun Yat-sen University
HAIC of FOLFOX Plus Sorafenib vs HAIC of FOLFIRINOX Plus Sorafenib for Advcanced HCC
Sun Yat-sen University
HAIC Plus Lenvatinib vs HAIC Plus Sorafenib for Advanced HCC
Sun Yat-sen University
Irradiation Stent Placement Plus TACE for HCC and PVTT
Zhongda Hospital
Sorafenib Monotherapy vs. TACE-sorafenib Sequential Therapy for HCC With Metastasis
Korea University
Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
Shanghai Jiao Tong University School of Medicine
SIRveNIB
Singapore General Hospital
HAIC of FOLFOX vs. HAIC of OXA for Advanced HCC
Sun Yat-sen University
A Trial to Compare Surgery With Sorafenib for Hepatic Celluler Cancer With Portal Vein Tumor Thrombosis
Huazhong University of Science and Technology
COTSOM
Asan Medical Center
TACTICS
Kindai University
Efficacy and Safety of Bevacizumab Plus Sorafenib for the Third-line Treatment in Metastatic Renal Cancer Patients
Peking University Cancer Hospital & Institute
REPEAT
Southwest Hospital, China
Radiofrequency Ablation Accompanied With Spontaneous Sorafenib in Early to Intermediate Stage HCC
Southwest Hospital, China
SEED
Seattle Children's Hospital
GITIC
Sun Yat-sen University
A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours
e-Therapeutics PLC
Sorafenib and TACE as Adjuvant Therapy for MVI in HCC Patients After Radical Resection
ChineseAMS